托法替布在类风湿关节炎治疗中的临床应用进展  

Clinical application progress of tofacitinib in rheumatoid arthritis

作　　者：陈水钫[1] 舒文琳[1] Chen Shuifang;Shu Wenlin(Department of Pharmacy,Xiamen Hospital of Traditional Chinese Medicine,Xiamen 361000,Fujian Province,China)

机构地区：[1]厦门市中医院药学部,厦门361000

出　　处：《中国基层医药》2022年第10期1594-1596,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：托法替布是一类治疗类风湿关节炎的新型靶向药物。随着进入医保目录,托法替布将迎来崭新的时代。该文分别对托法替布的疗效和安全性进行综述。总的说来,托法替布疗效确切,不良反应少,安全可控,与生物制剂相比,具有可以口服的优势,尤其适用于对传统合成的改善病情的抗风湿药和生物制剂疗效不佳或不能耐受的患者,但其在中国人群中的有效性和安全性尚需更多的研究数据来证实。Tofacitinib is a novel targeted drug for the treatment of rheumatoid arthritis.With the entry into the medical insurance catalogue,the drug will usher in a new era.This paper reviews the effectiveness and safety of tofacitinib in the treatment of rheumatoid arthritis.Generally speaking,tofacitinib has definite efficacy,few adverse reactions,and controllable safety.Tofacitinib has an advantage over biological agents,that is,tofacitinib can be orally administered.Therefore,tofacitinib is especially developed for patients who have a poor response to or who are intolerant to disease-modifying antirheumatic drugs and biological agents.However,the effectiveness and safety of tofacitinib in a Chinese population need to be confirmed by more studies.

关 键 词：关节炎 类风湿 分子靶向治疗 治疗结果 综述 托法替布 

分 类 号：R593.22[医药卫生—内科学]